GlassScriptPhysician profile
Karla Lundy
NPI 1487298279
$4,582.09
in general payments reported to CMS, 2019-2025
22 companies · $42.76 in 2025
The $42.76 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $2,669 · 2023: $1,665 · 2024: $14.34 · 2025: $42.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,108.98 | 2021-2024 | |
| Leo Pharma INC. | $633.03 | 2022-2023 | Adbry |
| Genzyme Corporation | $536.53 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $309.68 | 2022-2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $293.50 | 2021-2023 | Dupixent |
| Lilly USA, LLC | $272.80 | 2021-2023 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $242.49 | 2021-2023 | |
| Dermavant Sciences, INC. | $186.09 | 2022-2023 | Vtama |
| Amgen INC. | $164.00 | 2021-2023 | Otezla |
| Incyte Corporation | $138.56 | 2022-2023 | Opzelura |
| Ucb, INC. | $127.40 | 2022-2023 | Cimzia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.04 | 2022-2023 | Spevigo, Cyltezo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Sun Pharmaceutical Industries INC. | $82.95 | 2023 | Absorica Ld, Winlevi, Ilumya |
| Janssen Biotech, INC. | $71.78 | 2022-2023 | Tremfya |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.22 | 2021-2023 | |
| Medtronic, INC. | $25.12 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $24.85 | 2022 | |
| Dexcom, INC. | $22.29 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $20.47 | 2025 | The Cologuard Plus Collection Kit |
| Galderma Laboratories, L.P. | $18.53 | 2022 | |
| Almirall LLC | $16.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Lundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.